ESI-GROUP/ENSAM
3.5.2022 14:02:30 CEST | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Mnemo: ESI), a global simulation and virtual prototyping software partner for industry, announces the open-source release of its Inspector software; an opening for the scientific community, industrial collaboration, and innovation.
Inspector is a visual and interactive data exploration software that can analyze a large volume of data to extract useful information that can be applied in the following contexts: predictive maintenance, cybersecurity, control, and analysis of machine learning algorithms.
By making Inspector software available to as many people as possible, ESI Group continues its commitment to the industrial and academic ecosystems, offering them the possibility of working on a reliable and customizable solution to meet the technical challenges and specific needs of the community.
ENSAM (Ecole Nationale Supérieure d'Arts et Métiers) will lead the development and expansion of Inspector, as part of the continuum of sponsorship and co-creation activities already in progress between ESI Group and ENSAM. This collaboration has been reinforced with their mutual involvement in the DesCartes program led by the CNRS in Singapore, the CREATE-ID international research chair, and through the ESI - ENSAM virtual engineering laboratory .
This open-source approach has many advantages. First, it allows the community to use the software in an optimal and fast way, thus, enabling the scientific community to benefit from new functionalities adapted to the requirements of each user, as well as from security improvements. Secondly, through its approach, ESI Group wishes to offer an opportunity to benefit from a software whose reliability has been proven over the years by its customers in various industries, including Automotive and Aeronautics. “Inspector” will continue to evolve and adapt to the needs of the community thanks to the collaboration of the numerous stakeholders.
Several industry players and “Inspector” users have expressed interest and support for ESI Group's initiative to deploy its data analysis software in open source. This is the case, for example, with CNS.
Stephane Perrin, Managing Director of CNS states: "The decision taken by ESI Group is a great illustration of the Group’s dedication to the innovation and scientific ecosystem with its cutting-edge technologies. At CNS, a Network and Security expertise company, we are mobilized to ensure the future of Inspector. In addition to integrating Inspector into our continuous network auditing software suite, we will also soon offer support for the software via our business unit dedicated to innovative solutions."
Emmanuel Leroy, EVP Product, Innovation & Industry Solutions at ESI Group said: "Data and open source are the two main keywords of this new coordinated action with ENSAM. We are delighted to be able to take our collaboration a step further while contributing to academic and industrial research and innovation. "Inspector" will provide users with a tool for analyzing large volumes of data to optimize the performance of manufacturing processes. In a period where data is becoming key but remains expensive; I am convinced that this open-source release will open opportunities for industrial players, whether they are large companies or startups."
Information on how to obtain the Inspector download and installation links
The "Inspector" module can be retrieved as an archive (674MB) with the following command: sftp inspector@jibleo.com :source_code/inendi-inspector_opensource_export_2022-01-27.tgz.
The password associated with the SFTP account "inspector" is "ut!iep2E" and the checksum sha256 of the archive is d0404dd13c80ec8a4e32f406986731025881097ed03fa47a4af77827744f1000
The location of the Gitlab project from which the export was made is the following: https://gitlab.com/inendi/inspector
The software can now be installed with the following command (as indicated in the documentation on the Gitlab project homepage): flatpak install --user -y https://inendi.gitlab.io/inspector/install.flatpakref
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high-level specialists around the world and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom